INCY
Incyte Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +19.0% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | 0 | 3.15M | $378.92M | n/a | n/a |
| Q2 2026 | 156 | 0 | 132.96M | $15.07B | +4 | −3 |
| Q1 2026 | 158 | +1 | 132.61M | $12.47B | +5 | −5 |
| Q4 2025 | 156 | -1 | 139.13M | $13.74B | +1 | −1 |
| Q3 2025 | 24 | 0 | 89.63M | $7.60B | n/a | −1 |
| Q2 2025 | 22 | +1 | 88.20M | $6.01B | +1 | n/a |
| Q1 2025 | 18 | -1 | 44.33M | $2.68B | n/a | −1 |
| Q4 2024 | 19 | +1 | 43.85M | $3.03B | +1 | n/a |
| Q3 2024 | 17 | 0 | 35.50M | $2.35B | +1 | −1 |
| Q2 2024 | 17 | n/a | 33.47M | $2.03B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Robeco Institutional Asset… | 2.20M | -9.9% | $267.04M | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 2 | Assetmark, Inc | 520.37K | +1107.1% | $63.15M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 3 | Wealth Enhancement Advisory… | 236.32K | +56.0% | $25.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Assenagon Asset Management S.A. | 121.83K | +727.8% | $14.78M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | TD Waterhouse Canada Inc. | 75.35K | +97757.1% | $8.83M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 805 holders, 201.47M shares, $18.13B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.64K sh · $297,780
Officer · 13.98K sh · $1.69M
Officer · 9.23K sh · $1.11M
Officer · 10.80K sh · $1.36M
Officer · 10.80K sh · $1.30M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology